Report cover image

Mirabegron Sustained-release Tablets Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 06, 2025
Length 128 Pages
SKU # APRC20260135

Description

Summary

According to APO Research, the global Mirabegron Sustained-release Tablets market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Mirabegron Sustained-release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Mirabegron Sustained-release Tablets, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mirabegron Sustained-release Tablets.

The report will help the Mirabegron Sustained-release Tablets manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Mirabegron Sustained-release Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mirabegron Sustained-release Tablets market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Mirabegron Sustained-release Tablets Segment by Company

Alkem Laboratories
Astellas Pharma
Lupin Pharmaceuticals
Zydus Lifesciences
China Resources Pharmaceutical
Jiangsu Huayang Pharmaceutical
Jiangxi Shanxiang Pharmaceutical
Qilu Pharmaceutical
Shenzhen Main Luck Pharmaceuticals
CSPC Pharmaceutical
Sichuan Gowell Pharmaceutical
Zhejiang Huayi Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet
50mg per Tablet
Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic
Pharmacy
Other
Mirabegron Sustained-release Tablets Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mirabegron Sustained-release Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mirabegron Sustained-release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

128 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Mirabegron Sustained-release Tablets Market Size (2020-2031)
2.2.2 Global Mirabegron Sustained-release Tablets Sales (2020-2031)
2.2.3 Global Mirabegron Sustained-release Tablets Market Average Price (2020-2031)
2.3 Mirabegron Sustained-release Tablets by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 25mg per Tablet
2.3.3 50mg per Tablet
2.4 Mirabegron Sustained-release Tablets by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital and Clinic
2.4.3 Pharmacy
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Mirabegron Sustained-release Tablets Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Mirabegron Sustained-release Tablets Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Mirabegron Sustained-release Tablets Revenue of Manufacturers (2020-2025)
3.4 Global Mirabegron Sustained-release Tablets Average Price by Manufacturers (2020-2025)
3.5 Global Mirabegron Sustained-release Tablets Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Mirabegron Sustained-release Tablets, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Mirabegron Sustained-release Tablets, Product Type & Application
3.8 Global Manufacturers of Mirabegron Sustained-release Tablets, Established Date
3.9 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Alkem Laboratories
4.1.1 Alkem Laboratories Company Information
4.1.2 Alkem Laboratories Business Overview
4.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
4.1.5 Alkem Laboratories Recent Developments
4.2 Astellas Pharma
4.2.1 Astellas Pharma Company Information
4.2.2 Astellas Pharma Business Overview
4.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
4.2.5 Astellas Pharma Recent Developments
4.3 Lupin Pharmaceuticals
4.3.1 Lupin Pharmaceuticals Company Information
4.3.2 Lupin Pharmaceuticals Business Overview
4.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
4.3.5 Lupin Pharmaceuticals Recent Developments
4.4 Zydus Lifesciences
4.4.1 Zydus Lifesciences Company Information
4.4.2 Zydus Lifesciences Business Overview
4.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
4.4.5 Zydus Lifesciences Recent Developments
4.5 China Resources Pharmaceutical
4.5.1 China Resources Pharmaceutical Company Information
4.5.2 China Resources Pharmaceutical Business Overview
4.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.5.5 China Resources Pharmaceutical Recent Developments
4.6 Jiangsu Huayang Pharmaceutical
4.6.1 Jiangsu Huayang Pharmaceutical Company Information
4.6.2 Jiangsu Huayang Pharmaceutical Business Overview
4.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
4.7 Jiangxi Shanxiang Pharmaceutical
4.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
4.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
4.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
4.8 Qilu Pharmaceutical
4.8.1 Qilu Pharmaceutical Company Information
4.8.2 Qilu Pharmaceutical Business Overview
4.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.8.5 Qilu Pharmaceutical Recent Developments
4.9 Shenzhen Main Luck Pharmaceuticals
4.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
4.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
4.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
4.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
4.10 CSPC Pharmaceutical
4.10.1 CSPC Pharmaceutical Company Information
4.10.2 CSPC Pharmaceutical Business Overview
4.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.10.5 CSPC Pharmaceutical Recent Developments
4.11 Sichuan Gowell Pharmaceutical
4.11.1 Sichuan Gowell Pharmaceutical Company Information
4.11.2 Sichuan Gowell Pharmaceutical Business Overview
4.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.11.5 Sichuan Gowell Pharmaceutical Recent Developments
4.12 Zhejiang Huayi Pharmaceutical
4.12.1 Zhejiang Huayi Pharmaceutical Company Information
4.12.2 Zhejiang Huayi Pharmaceutical Business Overview
4.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
4.13 Chia Tai Tianqing Pharmaceutical
4.13.1 Chia Tai Tianqing Pharmaceutical Company Information
4.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
4.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
4.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Mirabegron Sustained-release Tablets Market Scenario by Region
5.1 Global Mirabegron Sustained-release Tablets Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2020-2031
5.2.1 Global Mirabegron Sustained-release Tablets Sales by Region: 2020-2025
5.2.2 Global Mirabegron Sustained-release Tablets Sales by Region: 2026-2031
5.3 Global Mirabegron Sustained-release Tablets Revenue by Region: 2020-2031
5.3.1 Global Mirabegron Sustained-release Tablets Revenue by Region: 2020-2025
5.3.2 Global Mirabegron Sustained-release Tablets Revenue by Region: 2026-2031
5.4 North America Mirabegron Sustained-release Tablets Market Facts & Figures by Country
5.4.1 North America Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
5.4.3 North America Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Mirabegron Sustained-release Tablets Market Facts & Figures by Country
5.5.1 Europe Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
5.5.3 Europe Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Mirabegron Sustained-release Tablets Market Facts & Figures by Country
5.6.1 Asia Pacific Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
5.6.3 Asia Pacific Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Mirabegron Sustained-release Tablets Market Facts & Figures by Country
5.7.1 South America Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
5.7.3 South America Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Mirabegron Sustained-release Tablets Market Facts & Figures by Country
5.8.1 Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2020-2031)
5.8.3 Middle East and Africa Mirabegron Sustained-release Tablets Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2031)
6.1.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2031) & (K Units)
6.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2020-2031)
6.2 Global Mirabegron Sustained-release Tablets Revenue by Type (2020-2031)
6.2.1 Global Mirabegron Sustained-release Tablets Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Type (2020-2031)
6.3 Global Mirabegron Sustained-release Tablets Price by Type (2020-2031)
7 Segment by Application
7.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2031)
7.1.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2031) & (K Units)
7.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Application (2020-2031)
7.2 Global Mirabegron Sustained-release Tablets Revenue by Application (2020-2031)
7.2.1 Global Mirabegron Sustained-release Tablets Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Application (2020-2031)
7.3 Global Mirabegron Sustained-release Tablets Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Mirabegron Sustained-release Tablets Value Chain Analysis
8.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Mirabegron Sustained-release Tablets Production Mode & Process
8.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Mirabegron Sustained-release Tablets Distributors
8.2.3 Mirabegron Sustained-release Tablets Customers
9 Global Mirabegron Sustained-release Tablets Analyzing Market Dynamics
9.1 Mirabegron Sustained-release Tablets Industry Trends
9.2 Mirabegron Sustained-release Tablets Industry Drivers
9.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
9.4 Mirabegron Sustained-release Tablets Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.